Wells Fargo (NYSE:WFC) analyst Larry Biegelsen maintained a Hold rating on Dexcom (NASDAQ:DXCM) on Friday, setting a price target of $475, which is approximately 4.16% above the present share price of $456.05.
Biegelsen expects Dexcom to post earnings per share (EPS) of $0.42 for the third quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Strong Buy rating of shares in Dexcom, with an average price target of $502.55.
The analysts price targets range from a high of $550 to a low of $450.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $505 million and a net profit of $45.9 million. The company's market cap is $44.1 billion.
According to TipRanks.com, Wells Fargo analyst Larry Biegelsen is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 21.9% and a 71.27% success rate.
California-based DexCom , Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.